Outlook Therapeutics Inc OTLK

$0.59 +0.02 (3.13%)

Valuation

Market cap
139,983,000
Revenue TTM
$1,410,000
Net income TTM
$-62,420,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,426.95%
Debt to equity
-1.75

Trading

Volume
5,619,500
Avg volume
15,055,758
Day's range
$0.57 – $0.61
Shares out
243,448,000
Stochastic %K
34%
Beta
0.66
Analysts
Sell
Price target
$5.03

Price

Company profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outl...

Show more

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
609 619 3990
Website
https://outlooktherapeutics.com
Address
111 S. Wood Avenue, Unit #100, Iselin, United States

Latest news

Stocktwits

AnalystLLM Oct 3, 11:14 PM
$OTLK it is really bullshit if you read the post and decide to invest or not. But your target or direction is correct and only one thing to correct. Who or which to listen? With my opinion, (1) GMS owner who invest 100m in the company if the commercial fails, he will lose 80% of money (2) COR 5.5B investment in RCA. The 5.5B itself will be stupid if it stops and not merge with OTLK. But how could it turns? Very simple, Lytenava is to replace Avastin with $100-$150 on 6m injection volume per year. It is a reality check and no illusion.
0 replies
Zybbi Oct 3, 6:41 PM
$OTLK LYTENAVA — 25% conversion from Avastin: Period: November–December; Wholesale Acquisition Cost (WAC): $485. 100 clinics → $3.0 million 150 → $4.6 million 200 → $6.1 million 300 → $9.1 million Key factors: reimbursement, pricing policy, market access, and product launch execution—including Andrea Sandefur’s role in market access.
0 replies
DidYouReadThis Oct 3, 5:03 PM
$OTLK #aging #meow my #eyes aren’t getting any #younger
1 replies
DidYouReadThis Oct 3, 5:02 PM
$OTLK
0 replies
DidYouReadThis Oct 3, 5:01 PM
$OTLK
0 replies
DidYouReadThis Oct 3, 5:01 PM
$OTLK
0 replies
DidYouReadThis Oct 3, 5:01 PM
$OTLK
0 replies
DidYouReadThis Oct 3, 4:59 PM
What did the #CATT #trial say? $IWM $SPY $ #saturday #meowchallenge till $OTLK #trends every #saturday #catturday #caturday #MEOW #meow #meow #MEOW #trending #yet? Congrats on FDA approval $OTLK!
0 replies